

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

ZAVIALOV et al.

09/424,080

Conf.:

Appl. No.: Filed:

Group: 1644

February 14, 2000 Examiner: M. Jamroz

7527

For:

COMPOSITIONS FOR ENHANCING

IMMUNOSUPPRESSANTS' PHARMACEUTICAL ACTIVITIES

REPLY TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, DC 20231

(Tuesday after Fed. Holiday)

Sir:

In reply to the Restriction Requirement dated October 12, 2001, the following remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION

Please replace the paragraph beginning at page 4, line 16 with the following paragraph.

Recently, the attention was brought to the long-neglected role of type I interferons (INF- $\alpha,\beta,\omega,\tau)$ in the modulation of immune response (Belardelli F. and Gresser I., 1996, Immunol. Today 17, pp. 369-372). The immunomodulating activity of IFN- $\alpha, \beta, \omega, \tau$ is very complex and includes: